vs
Side-by-side financial comparison of Astria Therapeutics, Inc. (ATXS) and Pineapple Financial Inc. (PAPL). Click either name above to swap in a different company.
Pineapple Financial Inc. is the larger business by last-quarter revenue ($707.3K vs $706.0K, roughly 1.0× Astria Therapeutics, Inc.). Pineapple Financial Inc. runs the higher net margin — -2756.2% vs -4482.0%, a 1725.8% gap on every dollar of revenue.
Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for rare hematological and allergic diseases with high unmet medical needs. Its core pipeline includes drug candidates designed to address life-threatening immune-mediated conditions, serving patient populations across North America and other global markets with limited existing treatment options.
ATXS vs PAPL — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $706.0K | $707.3K |
| Net Profit | $-31.6M | $-19.5M |
| Gross Margin | — | 48.9% |
| Operating Margin | -4830.6% | -2518.8% |
| Net Margin | -4482.0% | -2756.2% |
| Revenue YoY | — | -4.8% |
| Net Profit YoY | -29.0% | -3174.1% |
| EPS (diluted) | $-0.55 | $-1.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $707.3K | ||
| Q4 25 | — | $721.7K | ||
| Q3 25 | $706.0K | $730.5K | ||
| Q2 25 | — | $746.9K | ||
| Q1 25 | — | $743.3K | ||
| Q4 24 | — | $766.1K | ||
| Q3 24 | $0 | $598.3K | ||
| Q2 24 | — | $736.4K |
| Q1 26 | — | $-19.5M | ||
| Q4 25 | — | $-6.4M | ||
| Q3 25 | $-31.6M | $-1.8M | ||
| Q2 25 | — | $-557.7K | ||
| Q1 25 | — | $-595.4K | ||
| Q4 24 | — | $-656.9K | ||
| Q3 24 | $-24.5M | $-1.7M | ||
| Q2 24 | — | $-848.6K |
| Q1 26 | — | 48.9% | ||
| Q4 25 | — | 49.6% | ||
| Q3 25 | — | 27.8% | ||
| Q2 25 | — | 67.6% | ||
| Q1 25 | — | 43.4% | ||
| Q4 24 | — | 45.9% | ||
| Q3 24 | — | 43.2% | ||
| Q2 24 | — | 44.2% |
| Q1 26 | — | -2518.8% | ||
| Q4 25 | — | -909.1% | ||
| Q3 25 | -4830.6% | -131.3% | ||
| Q2 25 | — | -93.3% | ||
| Q1 25 | — | -80.6% | ||
| Q4 24 | — | -90.5% | ||
| Q3 24 | — | -232.8% | ||
| Q2 24 | — | -121.7% |
| Q1 26 | — | -2756.2% | ||
| Q4 25 | — | -891.6% | ||
| Q3 25 | -4482.0% | -250.3% | ||
| Q2 25 | — | -74.7% | ||
| Q1 25 | — | -80.1% | ||
| Q4 24 | — | -85.7% | ||
| Q3 24 | — | -283.9% | ||
| Q2 24 | — | -115.2% |
| Q1 26 | — | $-1.21 | ||
| Q4 25 | — | $-4.79 | ||
| Q3 25 | $-0.55 | $-0.93 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | — | $-1.73 | ||
| Q4 24 | — | $-2.60 | ||
| Q3 24 | $-0.42 | $-11.10 | ||
| Q2 24 | — | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $227.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $233.3M | $27.1M |
| Total Assets | $271.9M | $48.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $227.7M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $344.3M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $27.1M | ||
| Q4 25 | — | $-5.5M | ||
| Q3 25 | $233.3M | $906.7K | ||
| Q2 25 | — | $842.6K | ||
| Q1 25 | — | $739.7K | ||
| Q4 24 | — | $1.3M | ||
| Q3 24 | $341.7M | $1.3M | ||
| Q2 24 | — | $2.0M |
| Q1 26 | — | $48.9M | ||
| Q4 25 | — | $10.6M | ||
| Q3 25 | $271.9M | $5.4M | ||
| Q2 25 | — | $4.7M | ||
| Q1 25 | — | $4.0M | ||
| Q4 24 | — | $4.1M | ||
| Q3 24 | $361.6M | $4.1M | ||
| Q2 24 | — | $4.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-32.3M | $-3.3M |
| Free Cash FlowOCF − Capex | — | $-3.3M |
| FCF MarginFCF / Revenue | — | -462.7% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-3.3M | ||
| Q4 25 | — | $-489.7K | ||
| Q3 25 | $-32.3M | $-507.6K | ||
| Q2 25 | — | $397.0K | ||
| Q1 25 | — | $-172.6K | ||
| Q4 24 | — | $-663.6K | ||
| Q3 24 | $-28.0M | $-264.7K | ||
| Q2 24 | — | $123.0K |
| Q1 26 | — | $-3.3M | ||
| Q4 25 | — | $-491.7K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-28.0M | $-264.7K | ||
| Q2 24 | — | $122.7K |
| Q1 26 | — | -462.7% | ||
| Q4 25 | — | -68.1% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -44.2% | ||
| Q2 24 | — | 16.7% |
| Q1 26 | — | 0.0% | ||
| Q4 25 | — | 0.3% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
